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Abstract: 27 
Introduction: 28 
Continuous glucose monitoring (CGM) allows assessment of day to day glycaemic 29 
excursions and detects early glucose handling abnormalities that may not be 30 
apparent on oral glucose tolerance testing (OGTT). However, there is little published 31 
evidence as to whether these early dysglycaemic changes are amenable to 32 
treatment. We present outcomes following CGM guided insulin initiation at our 33 
centre. 34 
 35 
Methods 36 
Adults without a prior diagnosis of cystic fibrosis related diabetes (CFRD) whom 37 
underwent >72 hours CGM at our adult CF centre were included in the study. Clinical 38 
outcomes including weight and pulmonary function changes over the next 12 months 39 
were compared between groups based on CGM results and subsequent 40 
management. 41 
Results 42 
CGM profiles for 59 patients were analysed. Insulin was commenced in 37 patients 43 
who had evidence of hyperglycaemia on CGM. Significant improvements in mean 44 
[95% confidence intervals] forced expiratory volume in 1 second (FEV1) (+4.3% 45 
predicted [1.06-7.48], p=0.01) and weight (+1.2kg [0.32-2.15], p=0.01) were observed 46 
at 3 months in the insulin group. Annual rate of pulmonary function decline was also 47 
improved following insulin initiation. 48 
Conclusion 49 
Insulin treatment targeted towards glycaemic excursions seen on CGM is associated 50 
with improvements in lung function and weight with subsequent reduced pulmonary 51 
function decline.  52 
 53 
1. Introduction 54 
 55 
Increasing survival in cystic fibrosis (CF) has brought increasing co-morbidities, the 56 
most common of which is cystic fibrosis related diabetes (CFRD) occurring in up to 57 
50% of adults.[1] The mechanisms underpinning CFRD are incompletely understood, 58 
however its pathogenesis appears to be driven by progressive insulin deficiency with 59 
insulin resistance, incretin axis abnormalities, and primary cystic fibrosis 60 
transmembrane conductance regulator (CFTR) protein dysfunction playing 61 
contributory roles.[2-6] CFRD is associated with increased pulmonary exacerbations, 62 
increased mortality and accelerated pulmonary function decline often preceding the 63 
point at which diagnosis is made.[1, 7, 8]  64 
Traditional guidelines consider that a diagnosis of diabetes mellitus should be based 65 
upon the glycaemic response to a 75 g oral glucose load (the oral glucose tolerance 66 
test, OGTT), where glucose cut-off thresholds are those associated with an 67 
increased incidence of macro-vascular disease in an ageing population.[9] However 68 
in CF, dysglycaemia is a dynamic process due to variable insulinopenia, a 69 
heightened metabolic rate during inter-current infection, and poorer respiratory 70 
outcomes occur at a lower threshold of glucose intolerance. Furthermore, risk of 71 
microvascular dysfunction is higher in CF and therefore lower thresholds for 72 
diagnosis and treatment may be appropriate. [10] The OGTT is a static test that may 73 
not detect these early glucose handling abnormalities and is uncomfortable for 74 
patients: it is therefore less appropriate for people with CF, who have a high 75 
treatment burden and some form of dynamic glucose measurement is indicated. In 76 
keeping with this, the latest CF guidelines indicate that glucose monitoring over a 77 
period of time is more appropriate, even when the OGTT is first used. [11] 78 
Continuous glucose monitoring (CGM) is one such strategy and involves the use of a 79 
small sensor sited in the subcutaneous interstitial fluid that makes frequent glucose 80 
measurements. These devices are worn for three to five days and hence enable an 81 
accurate glucose profile to be visualised. CGM has been validated in the CF 82 
population and can detect glucose handling abnormalities otherwise missed by an 83 
OGTT.[12-14]  84 
Our practice is to use CGM to identify patients who may benefit from intervention and 85 
also to optimise management in those with CFRD.  In this study we investigate the 86 
impact of CGM guided insulin initiation on clinical outcomes. 87 
2. Methods: 88 
2.1 Study population and clinical parameters 89 
Adults with CF but without a previous diagnosis of CFRD (as defined by prior use of 90 
hypoglycaemic agents, diabetic OGTT or abnormal CGM) who had undergone CGM 91 
at our centre between 2013 and 2016 were included. Transplant recipients were 92 
excluded. Baseline clinical parameters are shown in Table 1. For change in lung 93 
function, the best  % predicted forced expiratory volume in 1 second (FEV1)  94 
calculated using Global Lung Function Initiative (GLI) reference values was 95 
compared one year before and after CGM, and for shorter term outcomes at 3 96 
months before and after respectively. [15] For changes in nutritional state, weight 97 
was recorded similarly at 3 and 12 months pre and post CGM. Total intravenous 98 
antibiotic days were noted during the year before and after CGM.   99 
2.2 CGM profiling and treatment.  100 
CGM was performed as per local protocol at our centre. Briefly, CGM devices 101 
(Freestyle Navigator, Abbott UK) were worn for up to 5 days and calibrated with self-102 
measurement blood glucose (SMBG) five times across the first 72 hours of 103 
monitoring. Results were accepted where there was at least 72 hours monitoring and 104 
appropriate calibration. Subjects completed a food and exercise diary for the entire 105 
CGM period which was reviewed in conjunction with the downloaded glucose profile.  106 
Glucose levels >7.8mmol/L for >4.5% of the whole CGM period were considered 107 
significantly hyperglycaemic as previously described [16], the remainder were 108 
classed as “normal”.  In those with hyperglycaemia, if there were clear triggers in the 109 
food diary amenable to dietary modification, e.g. sugary soft-drinks or sub-optimal 110 
pancreatic enzyme supplementation, a period of dietary modification was advised 111 
(dietary modification group). If there were no triggers amenable to dietary 112 
modification insulin therapy was considered (insulin group). Local protocol for insulin 113 
initiation consists of insulin detemir once daily but alternative regimes are considered 114 
after taking the CGM glycaemic profile, patient choice and lifestyle into account. 115 
2.3 Statistical analysis: 116 
Statistical analysis was performed using R (R Foundation for Statistical Computing, 117 
Vienna, Austria). Baseline clinical characteristics are presented as mean and 118 
standard deviation for continuous variables and count and percentage for categorical 119 
variables. 95% confidence intervals are given for the outcome variables. Elsewhere, 120 
differences between independent groups were calculated by Mann-Whitney or 121 
unpaired t-test for non-parametric and parametric results respectively.  Differences in 122 
clinical parameters before and after treatment were calculated using a paired t-test.  123 
 124 
3. Results  125 
The CGM profiles of 59 adults with CF (mean age [SD] 28 [9] years, mean FEV1 64.9 126 
[22.0] %predicted, 58% male) formed the dataset (Table 1). Average CGM period 127 
was 4899 minutes (3.4 days). The most frequent indication for CGM (27/59 episodes, 128 
46%) was an elevated capillary blood glucose during an inpatient stay or at annual 129 
screen. An unexplained drop in FEV1, unexplained weight loss or osmotic symptoms 130 
accounted for 21/59 (36%), 7/59 (12%) and 3/59 (5%) respectively.   131 
3.1 Clinical Parameters at CGM 132 
At CGM 52/59 (88%) had evidence of dysglycaemia: 15/52 (29%) had clear 133 
nutritional triggers and dietary modification was advised whilst the remaining 37 134 
(71%) were treated with insulin. 35/37 (94.6%) were commenced on insulin detemir 135 
once daily (average [range] initial dose 4.9 units [2-10]) and 2/37 (5.4%) insulin lispro 136 
2 units. Time spent above 7.8mmol/L was inversely associated with baseline FEV1 137 
(r= -0.38, p<0.01) and also FEV1 decline in the preceding year (r=-0.31, p=0.01). At 138 
baseline there were no differences in age, sex, P. aeruginosa colonisation or 139 
genotype, but the insulin group had poorer mean lung function than the dietary 140 
modification and normoglycaemic groups (% predicted FEV1 56.7% vs. 79.7% and 141 
76.6% respectively, p<0.001), had more IV days in the preceding year (37 days vs. 6 142 
days and 13.1 days respectively, p<0.01) and a lower weight (61.2 kg vs. 74.1 kg 143 
and 69.0 kg respectively, p<0.01). 144 
A moderate positive correlation was observed between time spent with blood glucose 145 
>7.8mmol/l and HbA1c (r=0.376, p<0.01). Of those with evidence of abnormal 146 
glucose handling, 37/52 (71%) had at least one excursion >11.2mmol/L, and 28/52 147 
(59%) spent >1% of time above 12mmol/L.  Hypoglycaemic episodes (<4.0mmol/L) 148 
were equally prevalent between the hyperglycaemic and normal groups (29% and 149 
36% respectively, p=0.12).  Mean annual decline (SD) in % predicted FEV1 was -150 
0.4%/yr (2.1), -1.3%/yr (3.7) and -1.74%/yr (2.9) for the normal, dietary modification 151 
and insulin initiation groups respectively. 152 
3.2 Outcomes 153 
Clinical outcomes are presented in table 2. In the insulin group improvements were 154 
observed in % predicted FEV1 (+4.27% [1.1-7.48] p=0.01, see Figure 1A) and weight 155 
(+1.2kg [0.3-2.1], p=0.01, see Figure 1B) in the first 3 months of treatment and 156 
although at 12 months treatment lung function was no longer significantly greater 157 
than pre-treatment, the rate of pulmonary function decline had significantly improved 158 
(+1.92%/yr, p=0.02). No differences in annual intravenous antibiotic days were 159 
observed following insulin initiation.  160 
For those individuals who did not require insulin or dietary modification, no significant 161 
differences were seen in weight (-0.66kg, [95% CI -1.91-0.6], p=0.22), lung function 162 
(+1.1% [ -4.9-2.7], p=0.49) lung function change (+0.01% [-1.82-1.84], p=0.99) or IV 163 
antibiotic usage (-1.4 days [-12.7- 9.8], p=0.06) for the period before and after CGM. 164 
In the dietary modification group, there were no significant differences at 3 months, 165 
however at 12 months FEV1 was worse (-2.7% [-4.82-0.64], p=0.01) and average IV 166 
antibiotic days had increased (+4.6 days [0.6-8.68], p=0.02). 167 
In those receiving insulin there was no correlation between changes lung function or 168 
weight and the degree of hyperglycaemia (FEV1 change r=0.05, [-0.21-0.30], p=0.70; 169 
weight change r=0.17, [-0.08 -0.41], p=0.19).  170 
3.3 Repeat Studies 171 
Repeat CGM results were available in 30/37 (81%) individuals commenced on 172 
insulin, see Table S1. Average absolute reduction [95% CI] in time spent >7.8mmol/L 173 
was 8% [1-14.5]. Changes in average time spent in each glycaemic zone are 174 
presented in Figure 2. Again we tested whether improvements seen on repeat CGM 175 
correlated with improvements with clinical parameters but no correlations were 176 
observed for v, weight, IV days, or episodes of hypoglycaemia. 177 
3.4 Insulin responders 178 
32/37 (86.5%) of those commenced on insulin had improvement in weight and/or 179 
lung function at 3 months. Of these, 31/32 (97%) had HbA1c <48mmol/mol and 180 
20/32 (62.5 %) <40mmol/mol, see Figure 3. Only 7/32 insulin responders (21.9%) 181 
had more than one excursion >11.1mmol/l across their initial CGM monitoring period.  182 
4.   Discussion 183 
The aims of this study were to investigate the impact of CGM guided insulin initiation 184 
on clinical outcomes. Although CGM is well validated in CF as a tool to detect early 185 
clinically significant glucose handling abnormalities that may not be observed on an 186 
OGTT, [12-14] whether these early abnormalities are amenable to treatment is not 187 
well established. For the first time, we have shown that CGM-guided insulin therapy 188 
can be associated with significant improvements in pulmonary function and weight.  189 
We found that increasing time spent with interstitial glucose levels >7.8mmol/L was 190 
associated with poorer baseline lung function and steeper pulmonary function decline 191 
in the year preceding CGM.  Insulin initiation based on this threshold was associated 192 
with improvements in lung function and weight and furthermore the subsequent rate 193 
of decline in lung function had been slowed. These findings are consistent with our 194 
previous work demonstrating that insulin improves nutritional state and temporarily 195 
improves pulmonary function in people with CFRD.[17] 196 
CGM use in CF was first validated over 13 years ago but until recently it was not 197 
incorporated into formal CFRD guidelines and its use in the CF community remains 198 
heterogeneous. CGM is an accurate screening tool for CFRD that has significant 199 
advantages over an OGTT. Firstly, the longer and more frequent monitoring period 200 
allows a more sensitive assessment of lower degrees of dysglycaemia which are 201 
clinically significant in people with CF but may be missed by an OGTT.  Secondly, it 202 
provides a “real world” assessment of glucose handling and hence can identify the 203 
response to mixed meals, drinks and exercise that an artificial single fasting glucose 204 
load cannot. These and the logistically intense nature of an OGTT make it a less 205 
appealing diagnostic strategy and previous reports have suggested less than half of 206 
centres use OGTT routinely. [18] 207 
The threshold of 4.5% of time spent above 7.8mmol/L was first identified as 208 
predicting clinical decline in children with CF and to our knowledge this is the first 209 
study to demonstrate its validity in the adult settling. [16] A number of other CGM 210 
parameters have been suggested including the presence of any reading >11mmol/L 211 
[19, 20], mean glucose [13], and more recently the usefulness of interquartile range 212 
and glycaemic variability have been introduced. [21, 22] A threshold based on a 213 
continuous outcome (e.g. % time spent >7.8mmol/L) rather than binary outcome (e.g. 214 
presence of any value >11mmol/L) allows quantification of the level of dysglycaemia 215 
which can be useful for monitoring treatment response. Furthermore, the cut-off of 216 
7.8mmol/L has biologic plausibility in that airway glucose concentration begins to 217 
increase once blood glucose rises above 8mmol/L.[23] Increased airway glucose 218 
concentration has been associated with acquisition of respiratory pathogens and 219 
hence may play a role in the deleterious clinical outcomes associated with CFRD.[23, 220 
24] Further work is required to establish whether 4.5% is the optimal quantum upon 221 
which treatment should be initiated.  222 
Interestingly, we did not observe any correlation between degree of hyperglycaemia 223 
and clinical improvement following insulin initiation. This may simply be because this 224 
study was not powered to detect such a change or that poorer glycaemic control 225 
requires a longer time to optimise and was not captured in the follow-up period. 226 
Alternatively, it may demonstrate that insulin is uniformly beneficial for those with 227 
CFRD and also those in the “pre-diabetic” stage. Pre-diabetes, otherwise termed 228 
glucose intolerance or impaired glucose tolerance, represents relative insulin 229 
deficiency, which is associated with excess protein catabolism, a pro-inflammatory 230 
state and deleterious pulmonary and nutritional outcomes in CF. [25, 26] Hence, one 231 
explanation for the apparent lack of relationship between improved clinical outcomes 232 
and glycaemic control is that improvements associated with insulin therapy may be 233 
mediated by its anabolic  and anti-inflammatory properties in addition to its glucose 234 
lowering properties.[27] 235 
Where there are clear nutritional triggers for glycaemic excursions our practice has 236 
been to advise dietary modification in the first instance. We found this strategy was 237 
associated with increased weight loss and intravenous antibiotic use perhaps 238 
suggesting this group may also require insulin. However, it must be considered that 239 
numbers in this group were small and unfortunately compliance data was not 240 
collected hence it is unclear whether the dietary recommendations were adhered to. 241 
Larger studies elsewhere have previously shown that increased nutritional 242 
intervention can be associated with maintained nutritional status in the “pre-diabetic” 243 
phase. [28] 244 
The recent emergence of a primary role for CFTR in beta cell function , together with 245 
the understanding that CF may associated with a degree of abnormal glucose 246 
metabolism from birth has led to the question of when to commence insulin treatment 247 
becoming more pertinent. [6, 29, 30] Whilst the distinction between impaired glucose 248 
tolerance and diabetes may be relevant in the management of conventional diabetes, 249 
earlier treatment may be of benefit in CF where deleterious clinical outcomes occur 250 
with dysglycaemia and there is excess mortality later in frank CFRD. [31] Equally, as 251 
the life-expectancy of people with CF increases the cardiovascular consequences of 252 
hyperglycaemia may become more prevalent in the CF population, particularly with 253 
the increased vascular dysfunction previously found in relatively healthy people with 254 
CF. [32] Thus, further underlining the potential importance of early treatment and 255 
optimal control of dysglycaemia. A number of small studies have investigated the use 256 
of early insulin in CF and most have demonstrated improvement in clinical outcomes 257 
although the overall quality of evidence in this area remains poor and larger 258 
prospective studies remain a priority. [26, 33-35] 259 
A limitation of the present study is that it is single-centre and hence its 260 
generalisability is uncertain. We have treated adults with CF with insulin based on 261 
CGM findings alone and although no changes in clinical outcomes were observed in 262 
the group who did not receive insulin, the lack of a true control or comparator group 263 
means our findings must be confirmed by prospective trials. Furthermore, our use of 264 
CGM was targeted at specific individuals with, for example, unexplained clinical 265 
deterioration rather than in a screening program and hence the pre-test probability of 266 
a positive result in our cohort will be higher than seen across the whole non-diabetic 267 
CF population. Conversely, although we found CGM evidence of dysglycaemia in 268 
52/59 (88%) of CF subjects, higher than that reported by Leclercq et al [19], where  269 
26/52 (50%) non-diabetics had evidence of dysglycaemia, our findings were lower 270 
than recently reported by Taylor-Cousar et al [20], where 10/10 (100%) subjects with 271 
a normal OGTT had evidence of impaired glucose handling, but similar to those of 272 
Leon et al [36] where 13/14 (92.8%) subjects with a normal OGTT had evidence of 273 
dysglycaemia on CGM. The variation in study sizes and thresholds utilised for 274 
classification of dysglycaemia may partly explain the differing prevalence of CFRD 275 
seen across these studies. Although further criticism of our study could be that the 276 
dysglycaemia seen on CGM in our cohort might have been detected by OGTT, CGM 277 
is well validated in detecting abnormalities not apparent on OGTT, [19, 37, 38] and 278 
the mean Hba1c in the insulin treated group was <40mmol/mol, a cut-off below which 279 
only 6% have a positive OGTT. [39]   280 
In conclusion, we have demonstrated for the first time that insulin treatment based on 281 
CGM abnormalities alone can be associated with improved pulmonary function and 282 
weight in the short-term with reduced pulmonary function decline in the longer-term. 283 
Prospective clinical trials are needed to define optimal thresholds for early 284 
intervention. 285 
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  394 
Figure 1: Changes in lung function (A) and weight (B) over the study period. 395 
Insulin was commenced at time 0 for the insulin group. Data are presented as 396 
mean+/- SEM  397 
398 
 Figure 2:  Mean % CGM period spent in each glycaemic range pre and post 399 
insulin initiation. **p<0.01 ***p<0.001  400 
 401 
  402 
** 
*** 
 403 
Figure 3: HbA1c plotted against % of CGM period spent in hyperglycaemic range 404 
for those patients treated with insulin. Subjects who showed clinical response 405 
are represented in green circles, those who did not are represented in red 406 
diamonds. 407 
 408 
 409 
 410 
 411 
 412 
 413 
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 415 
Table 1: Baseline characteristics 416 
 
Normal 
Dietary 
modification  
 
Insulin p 
Total 7 15 37 
 Male (%) 3 (42.9) 3 (20.0) 19 (51.4) 0.12 
F508del homozygous (%) 3 (42.9) 9 (60.0) 26 (70.3) 0.35 
Age, years  (SD) 29.3 (8.6) 30.9 (10.2) 26.6 (8.24) 0.27 
P. aeruginosa (%) 5 (71.4) 13 (86.7) 32 (86.5) 0.58 
Pancreatic insufficiency (%) 4 (57.1) 12 (80.0) 33 (89.2) 0.11 
BMI (SD) 23.5 (4.6) 24.4 (3.9) 22.1 (3.9) 0.16 
HbA1c, mmol/mol (SD) 36.57 (4.5) 37.9 (3.7) 39.4 (4.8) 0.26 
Annual IV days (SD) 13.1 (14.5) 6.2 (6.4) 37.2 (39.9) 0.006 
FEV1, %predicted (SD) 76.6 (17.5) 79.7 (23.3) 56.7 (18.1) <0.001 
Weight, kg (SD) 69.04 (17.14) 74.13 (12.45) 61.2 (13.27) 0.009 
Annual FEV1 decline,  
% predicted (SD) -0.41 (2.10) -1.30 (3.67) -1.74 (2.89) 0.56 
  417 
Table 2:  Paired analysis of clinical outcomes following CGM grouped by 418 
intervention. 419 
  420 
 
 Mean 
 change  
(95% CI) 
p 
Mean  
Change 
(95% CI) 
p 
Mean change  
(95% CI)  
p 
Predicted FEV1 (%) 
3 month 1.1% 
 (-4.97,2.68) 
0.49 0.0%  
(-3.92,3.92) 
0.9 +4.27% 
 (1.06,7.48) 
0.01 
 
12 months 
-0.54% 
 (-4.8,5.86) 
0.81 
-2.7% 
 (-4.82,-0.64) 
0.01 
+1.07%  
(-0.88,3.01) 
0.27 
Weight (kg) 
3 months -0.66 
 (-1.91,0.6) 
0.25 +0.3  
(-2.49 ,1.89) 
0.77 +1.23 
 (0.32,2.15) 
0.01 
 
12 months 
0.41  
(-1.47,2.29) 
0.61 
-1.21  
(-2.47, 0.06) 
0.06 
+0.75  
(-0.32,1.81) 
0.17 
Annual change in  
predicted  FEV1 
12 months +0.01 
(-1.82,1.84) 
0.99 -2.57 
(-6.2,1.1) 
0.14 +1.92 
(0.21,3.63) 
0.02 
IV antibiotic days 
12 months 
-1.4 
(-12.7,9.8) 
0.79 
+4.6  
(0.6,8.68) 
0.02 
-1.5 
 (-9.8,12.7) 
0.79 
 Table S1: Changes in time spent in each glycaemic zone during CGM period 421 
for each group pre and post intervention. (Diet group n = 7, Insulin group 422 
n= 17) 423 
 
Diet group Insulin group 
 
Pre Post Pre Post 
>7.8mmol/L 11% 8% 24% 16% 
Euglycaemia 88% 91% 75% 84% 
<3.8mmol/L 1% 1% 1% 0% 
 424 
